This is an observational study to evaluate the incidence of delayed-onset nodules of YVOIRE Y-Solution 360, YVOIRE Y-Solution 540 or YVOIRE Y-Solution 720 injected into the facial skin layer.

Inclusion Criteria:

• Planned for YVOIRE Y-Solution 360 or 540 or 720 filler injection in facial area (except middle of the forehead, lips) for the volume enhancement or anti-wrinkle treatment.
• Male and female of 19 years or above age.
• Informed consent to participate in the study.
• Able to participate throughout the study period.

Exclusion Criteria:

• Prohibited in the Product Label.
• Have active or infectious skin disease in injection area.
• Autoimmune disease or HIV infected patient.
• Received immunosuppressive therapy within 2 weeks.
• Previously experienced Delayed-onset nodule after filler injection in facial area.
• Previously experienced Hypertrophic scar or Keloid.
• Have participated in an interventional clinical investigation within 30 days or plan to participate one during the study period.
• Ineligible for this clinical investigation as per Investigator's discretion.

Any healthy male and female whose filler injection on facial area is already planned for volume enhancement and anti-wrinkle treatment.

Incidence rate of delayed-onset nodule or other side effects when YVOIRE Y-Solution 360 or 540 or 720 are used.

The data is expected to be available during 2022.